Tilray¤j³Â²£«~Àò§å¥X¤f¬ü°ê
ªÑ»ù¤@Ó¤ëºÆº¦3¿
¡i©ú³ø±M°T¡j¥[®³¤j¤j³Â¥Í²£°ÓTilray©P¤G«Å¥¬¡A¥¦¤wÀò¬ü°ê½r¬r§½(U.S. Drug Enforcement Administration)³\¥i¡A¥i±N¤j³Â²£«~¿é©¹¬ü°ê°µÂåÀø¬ã¨s¡A®ø®§¥OTilrayªÑ»ù³sÄò²Ä¤G¤Ñ¤jº¦¡C
¦b¬ü°ê¤W¥«ªºTilray¡AªÑ»ù©P¤G¦Aº¦28.95%¡A©Î34.79¤¸¡A¦¬154.98¤¸¡C2,170¸U¬y³qªÑ¤¤¡A1,900¸UªÑ©ö¤â¡C¹L¥h¤@Ó¤ë¨Ó¡AªÑ»ù§ó¤W´¤F¶W¹L400%¡C
Tilray±N»P¸t¡¤à¥[¦{¤j¾Ç¦X§@¡A¶i¦æÃĥΤj³Â¬ã¨s¡A¤F¸Ñ¤j³Â¹ï¤@ºØ¯«¸g¨t²Î¯e¯fªºÃĮġB¦w¥þ¤Î@¨ü©Ê¡C
TilrayÁ{þH¬ã¨s³¡¥D¥ô³Ç§J¥¬´Ë(Catherine Jacobson)Âå¥Íªí¥Ü¡G¡u§Ú̬°¯à¤ä«ù¦¹¤@«n¬ã¨s·P¨ìź¶Æ¡C¦pªG³o¶µ¬ã¨s¯à°÷µo²{¤j³Â¯À(cannabinoids)¹ï¯Sµo©Ê¾_Ÿ(essential tremors)¦³¼ç¦bªºÂåÀø®ÄªG¡A§ÚÌ¥i¥H¦A¶i¤@¨B¬ã¨s¡A¨Ã¹ï¿©±w¯Sµo©Ê¾_Ÿªº¯f¤H´£¨Ñ¥t¤@ºØ¦³®ÄªºÀøªk¡C¡v
®Ú¾ÚTilrayºô¯¸¡A¯Sµo©Ê¾_Ÿ¬O¤@ºØ¯«¸g©Ê¹B°Ê»Ùê¡A¯S¼x¬O¤£¦Û¥D¥B³W«ßªº§Ý°Ê¡CTilray«ü¥X¡A¯Sµo©Ê¾_Ÿ¬ù¼vÅT¥[®³¤j0.4%¤H¤f¡A¨ä¤¤4.6%¦Ü6.3%³£¬O¦~ÄÖ¶W¹L65·³ªº¦Ñ¦~¤H¡C
Tilrayªº¥«È¸û¼Ð´¶500¤¤¥|¤À¤§¤@ªº¤½¥qÁÙn°ª¡A¾¨ºÞ¸Ó¤½¥q³Ìªñ¤@©uªºÀ禬¶È¬°970¸U¤¸¡C
Cowen¤ÀªR®v¦ã¿Aº¸(Vivien Azer)ªí¥Ü¡G¡u¤µ¤Ñªº·s»D¹ïTilray¤Î¾ãÓ¤j³Â·~¨ÓÁ¿³£¬O¦n®ø®§¡C¤j³ÂÃĥΥγ~¼W¥[¡A¥BÀò¬F©²¤ä«ù¡A±N¦³§U©ó¬ü°ê¥¼¨Ó¤]±N¹ê²{¤j³Â¦Xªk¤Æ¡C¡v
¦ã¿Aº¸¥ç«ü¥X¡ATilray»P¸t¡¤à¥[¦{¤j¾Ç¦X§@ªºÁ{þH¸ÕÅç¡A¤]¦³§U©óTilray¦bª¾ÃѲ£Åv¤W»PCanopy Growth©ó¬ü°ê¤Î¥þ²yÄvª§¡CCanopy Growth¥Ø«e¾Ö¦³39¶µ¬ü°ê±M§Q¤Î15¶µÁ{þH¸ÕÅç¡C